Hospital
Chesapeake Hospital LLC
Chesapeake Hospital LLC was paid $6.00M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoCHESAPEAKE HOSPITAL LLC
KILMARNOCK, VA 22482
KILMARNOCK, VA 22482
33aNPI1699125526assigned 06/22/2016
33bProvider typeCritical Access Hospital
28Total paid$6.00M
24GClaims105,254
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Virginia
Rank by total paid#4 of 8
Median peer was paid$893K
This provider vs. median6.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,332 | $95K | |
| 2019 | 12,535 | $483K | |
| 2020 | 10,954 | $572K | |
| 2021 | 16,545 | $746K | |
| 2022 | 22,459 | $1.14M | |
| 2023 | 21,068 | $1.47M | |
| 2024incomplete | 18,361 | $1.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 8,686 | 7,681 | $2.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 4,486 | 3,841 | $1.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 3,322 | 2,766 | $787K |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.6% | 1,358 | 1,052 | $458K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 1,874 | 1,650 | $382K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 836 | 729 | $208K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 573 | 510 | $205K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 1,429 | 969 | $156K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.2% | 974 | 908 | $130K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.3% | 181 | 114 | $77K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 1,145 | 1,082 | $69K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,353 | 1,260 | $58K |
75 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 256 | $57K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,100 | $42K |
| 80053 | Comprehensive metabolic panel | <1% | 6,692 | $31K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 851 | $31K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 54 | $27K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 353 | $25K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 245 | $22K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 375 | $18K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 92 | $18K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 421 | $15K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 298 | $13K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,200 | $12K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,205 | $11K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,986 | $9K |
| 85018 | <1% | 1,074 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,686 | $6K |
| 87040 | <1% | 820 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,128 | $5K |
| 87634 | <1% | 176 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,220 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,917 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,434 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 847 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,294 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,306 | $2K |
| 84484 | <1% | 2,917 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 330 | $2K |
| 73030 | <1% | 43 | $2K | |
| 81001 | <1% | 4,152 | $1K | |
| 83880 | <1% | 137 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 314 | $1K |
| 81003 | <1% | 423 | $890.37 | |
| 73562 | <1% | 91 | $860.47 | |
| 83605 | <1% | 1,138 | $841.55 | |
| 81025 | <1% | 1,694 | $778.51 | |
| 83735 | <1% | 1,987 | $778.40 | |
| 73630 | <1% | 43 | $638.66 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 983 | $619.15 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,503 | $551.42 |
| 82962 | <1% | 1,132 | $506.56 | |
| 73610 | <1% | 27 | $395.32 | |
| J3490 | Unclassified drugs | <1% | 1,078 | $381.83 |
| 87807 | <1% | 98 | $370.63 | |
| 85610 | <1% | 538 | $326.62 | |
| 82553 | <1% | 59 | $262.96 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 47 | $205.43 |
| 81002 | <1% | 60 | $203.33 | |
| 85379 | <1% | 76 | $180.70 | |
| 87070 | <1% | 1,145 | $179.33 | |
| 83690 | <1% | 1,603 | $153.97 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 471 | $140.57 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 17 | $113.51 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,129 | $91.01 |
| 80306 | <1% | 63 | $58.91 | |
| 82550 | <1% | 126 | $37.73 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 464 | $36.81 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 475 | $34.11 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 213 | $24.14 |
| 82077 | <1% | 102 | $16.64 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 75 | $7.21 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,223 | $6.91 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 62 | $6.34 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 33 | $5.52 |
| 96376 | <1% | 444 | $5.39 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 125 | $4.13 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 36 | $0.49 |
| 87186 | 0% | 16 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 14 | $0.00 |
| 94762 | 0% | 77 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 45 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 98 | $0.00 |
| 87147 | 0% | 30 | $0.00 | |
| 94760 | 0% | 17 | $0.00 | |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 18 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.